30 closest matches · ranked by relevance
Thymoma · Thymic Carcinoma · Thymic Carcinoid
Primary: Objective Response Rate (Partial Response (PR)+Complete Response (CR)) to IMC-A12 Monotherapy in Patients With Advanced or Recurrent Thymoma or Thymic Carcinoma. — 0; 0…
Thymoma · Thymic Carcinoma
Primary: Objective Response Rate (Complete and Partial Response) — 26.7; 9.1 percentage of participants
Thymoma · Thymic Carcinoma
Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 5; 6 Participants
Locally Advanced Thymic Carcinoma · Metastatic Thymic Carcinoma · Recurrent Thymic Carcinoma
Primary: Progression-free Survival — 8; 7 Months
Primary Inoperable Thymoma · Local Recurrent Thymoma
Primary: Percent Change in Tumor Volume From Baseline to EOS — -37.38 percentage of tumor volume
Thymoma · Thymus Neoplasms
Primary: Percentage of Participants With an Objective Response (Partial Response (PR) + Complete Response (CR) for Sunitinib in Participants With Relapsed or Refractory Thymoma…
Thymoma · Thymus Cancer · Thymic Carcinoma
Primary: Overall Response Rate (ORR) — 0; 6; 6 Participants
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.4 months
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control Rate (DCR) After 12 Weeks Induction — 0.742 proportion of participants
Non-Small Cell Lung Cancer
Primary: Overall Survival — 21.5; 24.1 Months — p=0.883
Thymoma · Thymic Carcinoma
Primary: Number of Participants With a Partial Response — 2; 0 Participants
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months
Thymoma
Primary: Percent of Patients With Objective Response — 7.1 percentage of participants
Lung Cancer
Primary: Overall Survival and Progression Free Survival — 29; 12.9; 22 percentage of participants
Lung Cancer
Primary: Toxic Death Rate — NA Participants
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Primary: 2-year Overall Survival (Phase II) — 66.5; 55.5 percentage of participants
Non-small Cell Lung Cancer, NSCLC
Primary: Progression-Free Survival (PFS) — 19 Participants
Carcinoma, Non Small Cell Lung (NSCLC)
Primary: The Metabolic Complete Response Rate, Assessed Using Interim PET-CT, in an Accelerated Fashion (2 Gy/Fraction, 6 Fractions/Week) With Concurrent Chemotherapy — 1; 6; 1…
Esophageal Cancer
Primary: Pathologic Complete Response (PCR) Rate
Lung Cancer
Primary: Pathologic Complete Response Rate — 0 Percentage of participants
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Non-small Cell Lung Cancer
Primary: Overall Survival (OS) Time — 32.4; 32.2 Months — p=0.828
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Esophageal Squamous Cell Carcinoma
Primary: Safety (Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events) — 13 Participants
Esophageal Squamous Cell Carcinoma
Primary: 1-year Relapse-free Survival Rate — 14.3 months
Lung Cancer
Primary: Number of Participants Whose Response Allowed Them to Proceed to Chemoradiation — 38 participants
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…